News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
380,956 Results
Type
Article (25905)
Company Profile (60)
Press Release (354991)
Multimedia
Podcasts (25)
Webinars (7)
Section
Business (104260)
Career Advice (449)
Deals (16871)
Drug Delivery (51)
Drug Development (47594)
Employer Resources (47)
FDA (12260)
Job Trends (8438)
News (185917)
Policy (19414)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (1749)
Accelerated approval (3)
Adcomms (8)
Allergies (70)
Alliances (26726)
ALS (55)
Alzheimer's disease (807)
Antibody-drug conjugate (ADC) (43)
Approvals (12315)
Artificial intelligence (160)
Autoimmune disease (10)
Automation (4)
Bankruptcy (142)
Best Places to Work (6893)
BIOSECURE Act (5)
Biosimilars (36)
Biotechnology (39)
Bladder cancer (46)
Brain cancer (17)
Breast cancer (180)
Cancer (1321)
Cardiovascular disease (111)
Career advice (407)
Career pathing (13)
CAR-T (66)
Cell therapy (191)
Cervical cancer (13)
Clinical research (40416)
Collaboration (422)
Compensation (124)
Complete response letters (9)
COVID-19 (1489)
CRISPR (11)
C-suite (130)
Cystic fibrosis (42)
Data (1422)
Decentralized trials (2)
Denatured (17)
Depression (28)
Diabetes (167)
Diagnostics (3509)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (13)
Drug discovery (51)
Drug pricing (53)
Drug shortages (21)
Duchenne muscular dystrophy (53)
Earnings (36785)
Editorial (19)
Employer branding (6)
Employer resources (44)
Events (51571)
Executive appointments (429)
FDA (13195)
Featured Employer (15)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (3)
Funding (388)
Gene editing (35)
Generative AI (10)
Gene therapy (123)
GLP-1 (393)
Government (3027)
Grass and pollen (3)
Guidances (35)
Healthcare (12187)
Huntington's disease (10)
IgA nephropathy (15)
Immunology and inflammation (38)
Indications (18)
Infectious disease (1558)
Inflammatory bowel disease (77)
Inflation Reduction Act (4)
Influenza (25)
Intellectual property (48)
Interviews (40)
IPO (7034)
IRA (19)
Job creations (1838)
Job search strategy (378)
Kidney cancer (7)
Labor market (9)
Layoffs (167)
Leadership (4)
Legal (3630)
Liver cancer (54)
Lung cancer (219)
Lymphoma (88)
Machine learning (2)
Management (17)
Manufacturing (99)
MASH (44)
Medical device (12872)
Medtech (12875)
Mergers & acquisitions (10116)
Metabolic disorders (414)
Multiple sclerosis (52)
NASH (11)
Neurodegenerative disease (46)
Neuropsychiatric disorders (9)
Neuroscience (1124)
NextGen: Class of 2025 (3930)
Non-profit (2820)
Northern California (1274)
Now hiring (16)
Obesity (214)
Opinion (69)
Ovarian cancer (50)
Pain (60)
Pancreatic cancer (52)
Parkinson's disease (88)
Partnered (11)
Patents (107)
Patient recruitment (71)
Peanut (37)
People (34666)
Pharmaceutical (18)
Pharmacy benefit managers (11)
Phase I (11584)
Phase II (17492)
Phase III (14376)
Pipeline (642)
Policy (57)
Postmarket research (1668)
Preclinical (3594)
Press Release (18)
Prostate cancer (70)
Psychedelics (17)
Radiopharmaceuticals (160)
Rare diseases (178)
Real estate (2846)
Recruiting (16)
Regulatory (14162)
Reports (16)
Research institute (1606)
Resumes & cover letters (48)
Rett syndrome (2)
RNA editing (2)
RSV (20)
Schizophrenia (47)
Series A (63)
Series B (45)
Service/supplier (3)
Sickle cell disease (21)
Southern California (1120)
Special edition (3)
Spinal muscular atrophy (102)
Sponsored (12)
Startups (2122)
Stomach cancer (8)
Supply chain (37)
Tariffs (7)
The Weekly (8)
United States (12213)
Vaccines (344)
Venture capitalists (13)
Weight loss (137)
Women's health (17)
Worklife (4)
Date
Today (62)
Last 7 days (265)
Last 30 days (1394)
Last 365 days (18638)
2025 (5110)
2024 (19855)
2023 (22748)
2022 (30691)
2021 (32988)
2020 (32192)
2019 (28412)
2018 (21810)
2017 (18906)
2016 (18112)
2015 (21194)
2014 (16023)
2013 (13241)
2012 (14349)
2011 (14622)
2010 (13181)
Location
Africa (354)
Alabama (17)
Alaska (2)
Arizona (116)
Arkansas (10)
Asia (24485)
Australia (3880)
California (2895)
Canada (1178)
China (343)
Colorado (158)
Connecticut (165)
Delaware (106)
Europe (47803)
Florida (517)
Georgia (124)
Idaho (33)
Illinois (348)
India (13)
Indiana (219)
Iowa (2)
Japan (109)
Kansas (72)
Kentucky (12)
Louisiana (6)
Maine (27)
Maryland (614)
Massachusetts (2037)
Michigan (104)
Minnesota (259)
Mississippi (2)
Missouri (51)
Montana (18)
Nebraska (18)
Nevada (30)
New Hampshire (59)
New Jersey (1080)
New Mexico (9)
New York (907)
North Carolina (539)
North Dakota (3)
Northern California (1274)
Ohio (124)
Oklahoma (3)
Oregon (23)
Pennsylvania (787)
Puerto Rico (7)
Rhode Island (23)
South America (520)
South Carolina (18)
Southern California (1120)
Tennessee (76)
Texas (508)
Utah (104)
Virginia (74)
Washington D.C. (38)
Washington State (218)
West Virginia (3)
Wisconsin (39)
380,956 Results for "ventus medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ventus Therapeutics Appoints Mona Kotecha, M.D., as Chief Medical Officer
February 19, 2025
·
2 min read
Press Releases
Ventus Therapeutics Announces Publication in Nature’s Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors
March 26, 2025
·
3 min read
Press Releases
Ventus Therapeutics Announces Nature Reviews Immunology Publication Demonstrating the Promise of Caspase-4/5 as Therapeutic Targets
March 6, 2025
·
4 min read
Press Releases
Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease
March 10, 2025
·
4 min read
Genetown
Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
Ventus Therapeutics, Inc announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference.
April 8, 2024
·
2 min read
Drug Development
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).
May 3, 2024
·
6 min read
Drug Development
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Ventus Therapeutics today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.
April 17, 2024
·
7 min read
Press Releases
Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor
October 31, 2024
·
3 min read
Ventus Therapeutics to Present at the Stifel 2023 Healthcare Conference
Ventus Therapeutics announced today that its President and Chief Executive Officer Marcelo Bigal, M.D., Ph.D., will present at the Stifel 2023 Healthcare Conference in New York.
November 9, 2023
·
2 min read
Drug Development
Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor
Ventus Therapeutics announced today that the first participant has been dosed in a Phase 1 clinical trial of VENT-03, the first cGAS inhibitor to advance into clinical development.
January 3, 2024
·
4 min read
1 of 38,096
Next
